Increasing Treatment Adherence in Co-Occurring Psychiatric & Drug Use

Status Completed

Clinical Trial Summary

The investigators are proposing a study of treatment adherence in co-occurring psychiatric and drug use disorders (COD). The proposed study uses a 3-cell/condition design, within which 75 adult outpatients with co-occurring psychiatric disorders and drug abuse/dependence (CODDA) will be randomly assigned to one of the following brief, 8-week, manual-guided interventions following a 2-week "Assessment Only" baseline period:

1. Adherence Feedback (AF); this condition will entail weekly, 20-25 minute sessions of AF, which is a procedure that represents a technological advancement developed by Cramer et al. (1989, 1995, and 1999) and is based on the use of adherence data from the microelectronic monitor in Medication Event Monitoring System (MEMS) caps,

2. AF + Contingency Management (AF + CM); in this condition, participants will receive AF, as described above, PLUS contingency management. CM is based on the behavioral learning theory, which suggests that the occurrence of a behavior is increased as a function of the rate at which it is positively reinforced or rewarded, or

3. AF + Motivational Enhancement Therapy (AF + MET); in this condition, patients will receive AF, as described above, PLUS motivational enhancement therapy. MET is based on the idea that an effective way to motivate behavior change is to assist patients in clarifying their ambivalence (i.e., reasons for and against changing/adhering), utilizing a series of strategies based on client-centered psychotherapy, self-efficacy theory, and social psychology.

The study will allow the evaluation of three hypotheses:

1. AF + MET is superior to AF + CM,

2. AF + MET is superior to AF alone, and

3. AF + CM is superior to AF alone.

Primary outcome measures are:

1. rates of adherence to medication (i.e., selective serotonin reuptake inhibitors or SSRIs), as measured by MEMS caps and self-report,

2. rates of counseling attendance, and

3. reductions in illicit drug use, including achievement of abstinence, as assessed by twice-weekly urine toxicology tests and self-report.

Secondary outcomes include reductions in psychiatric symptomatology and rates of re-hospitalization. The investigators will also evaluate the relationship between adherence and primary and secondary outcomes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00237822
Study type	Interventional
Source	Yale University
Contact
Status	Completed
Phase	Phase 2
Start date	September 2003
Completion date	December 2007

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06163651` - Evaluating a One-Year Version of the Parent-Child Assistance Program	N/A
Completed	`NCT02224508` - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks	N/A
Completed	`NCT01413529` - HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users	Phase 2
Completed	`NCT01141920` - Comparison of Two Counseling Induction Strategies	N/A
Completed	`NCT03678051` - CBT4CBT for Women in Residential Treatment for Substance Use Disorders	N/A
Recruiting	`NCT04003948` - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification	Phase 2
Active, not recruiting	`NCT03713983` - Treatment Outcomes Among Patients With Prescription Narcotic Drug Use Disorder
Active, not recruiting	`NCT02601495` - Latent Structure of Multi-level Assessments and Predictors of Outcomes for Women in Recovery
Recruiting	`NCT05534568` - The Oklahoma Parent-Child Assistance Program	N/A
Completed	`NCT04907045` - An Initial Study of the Implementation of Digital Therapeutics for Substance Use Disorders in Primary Care	N/A
Completed	`NCT04268173` - Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3	Phase 3
Not yet recruiting	`NCT06317987` - Addressing Barriers to Care for Substance Use Disorder Pilot Study	N/A
Completed	`NCT03373240` - Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention	N/A
Active, not recruiting	`NCT06249542` - Implementing Screening for Cannabis and Other Drug Use Disorders in Primary Care: Impact on Diagnosis and Treatment	N/A
Completed	`NCT02450240` - Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders
Recruiting	`NCT03069118` - 90-Day Online Substance Use Program	N/A
Active, not recruiting	`NCT05160233` - Digital Treatments for Opioids and Other Substance Use Disorders in Primary Care	N/A
Completed	`NCT03451344` - A Electronic System to Improve Recovery Outcomes in Patients With Drug Use Disorder	N/A
Completed	`NCT00798538` - Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)	Phase 4
Completed	`NCT03684252` - Reducing Self-stigma in Persons With HIV and Drug Use Disorders in Primary Health Care Settings	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Increasing Treatment Adherence in Co-Occurring Psychiatric and Drug Use Disorders

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms